Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers

DC FieldValueLanguage
dc.contributor.authorFattah, Sarinj-
dc.contributor.authorIsmaiel, Mohamed-
dc.contributor.authorMurphy, Brenda-
dc.contributor.authorBrayden, David James-
dc.contributor.authoret al.- the Authorsen_US
dc.identifier.citationEuropean Journal of Pharmaceutical Sciencesen_US
dc.description.abstractOctreotide is approved as a one-month injectable for treatment of acromegaly and neuroendocrine tumours. Oral delivery of the octapeptide is a challenge due mainly to low intestinal epithelial permeability. The intestinal permeation enhancer (PE) salcaprozate sodium (SNAC) has Generally Regarded As Safe (GRAS) status and is a component of an approved oral peptide formulation. The purpose of the study was to examine the capacity of salcaprozate sodium (SNAC), to increase its permeability across isolated rat intestinal mucosae from five regions and across human colonic mucosae mounted in Ussing chambers. Apical-side buffers were Kreb's-Henseleit (KH), fasted simulated intestinal fluid (FaSSIF-V2), rat simulated intestinal fluid (rSIF), and colonic simulated intestinal fluid (FaSSCoF). The basal apparent permeability coefficient (Papp) of [3H]-octreotide was equally low across rat intestinal regional mucosae in KH, rSIF, and FaSSIF-V2. Apical addition of 20 mM SNAC increased the Papp across rat tissue in KH: colon (by 3.2-fold) > ileum (3.4-fold) > upper jejunum (2.3-fold) > duodenum (1.4-fold) > stomach (1.4-fold). 20 mM and 40 mM SNAC also increased the Papp by 1.5-fold and 2.1-fold respectively across human colonic mucosae in KH. Transepithelial electrical resistance (TEER) values were reduced in the presence in SNAC especially in colonic regions. LC-MS/MS analysis of permeated unlabelled octreotide across human colonic mucosae in the presence of SNAC indicated that [3H]-octreotide remained intact. No gross damage was caused to rat or human mucosae by SNAC. Attenuation of the effects of SNAC was seen in rat jejunal mucosae incubated with FaSSIF-V2 and rSIF, and also to some extent in human colonic mucosae using FaSSCoF, suggesting interaction between SNAC with buffer components. In conclusion, SNAC showed potential as an intestinal permeation enhancer for octreotide, but in vivo efficacy may be attenuated by interactions with GI luminal fluid contents.en_US
dc.description.sponsorshipEuropean Commission Horizon 2020en_US
dc.description.sponsorshipScience Foundation Irelanden_US
dc.subjectUssing chamberen_US
dc.subjectIntestinal permeation enhancersen_US
dc.subjectOral peptide deliveryen_US
dc.subjectSimulated intestinal fluidsen_US
dc.titleSalcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambersen_US
dc.typeJournal Articleen_US
dc.statusPeer revieweden_US
dc.citation.otherArticle Number: 105509en_US
dc.neeo.contributorBrayden|David James|aut|-
dc.neeo.contributoret al.||aut|-
item.fulltextWith Fulltext-
Appears in Collections:Conway Institute Research Collection
Medicine Research Collection
Veterinary Medicine Research Collection
Files in This Item:
File Description SizeFormat 
EJPS Fattal Corrected proof.pdf1.39 MBAdobe PDFDownload
Show simple item record

Page view(s)

Last Week
Last month
checked on May 13, 2021


checked on May 13, 2021

Google ScholarTM



If you are a publisher or author and have copyright concerns for any item, please email and the item will be withdrawn immediately. The author or person responsible for depositing the article will be contacted within one business day.